Brookline Capital Markets Starts SQZ Biotechnologies (SQZ) at Buy

March 30, 2021 4:36 PM EDT
Get Alerts SQZ Hot Sheet
Price: $13.66 +1.04%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 42
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Brookline Capital Markets analyst Leah Rush Cann initiates coverage on SQZ Biotechnologies (NYSE: SQZ) with a Buy rating and a price target of $40.00.

The analyst commented, "We are initiating coverage of SQZ Biotech, a development-stage biotechnology company working in solid tumors cancers, autoimmune disease and infectious disease, with a Buy rating and a 12-18-month $40 target price."

For an analyst ratings summary and ratings history on SQZ Biotechnologies click here. For more ratings news on SQZ Biotechnologies click here.

Shares of SQZ Biotechnologies closed at $12.07 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage